GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » Shiller PE Ratio

Hansa Biopharma AB (OSTO:HNSA) Shiller PE Ratio : (As of Jun. 05, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Hansa Biopharma AB Shiller PE Ratio Historical Data

The historical data trend for Hansa Biopharma AB's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB Shiller PE Ratio Chart

Hansa Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hansa Biopharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hansa Biopharma AB's Shiller PE Ratio

For the Biotechnology subindustry, Hansa Biopharma AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansa Biopharma AB's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's Shiller PE Ratio falls into.



Hansa Biopharma AB Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Hansa Biopharma AB's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Hansa Biopharma AB's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-4.15/132.2054*132.2054
=-4.150

Current CPI (Mar. 2024) = 132.2054.

Hansa Biopharma AB Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.180 100.432 -0.237
201409 -0.200 100.161 -0.264
201412 -0.470 100.225 -0.620
201503 -0.390 99.950 -0.516
201506 -0.700 99.995 -0.925
201509 -0.430 100.228 -0.567
201512 -0.580 100.276 -0.765
201603 -0.610 100.751 -0.800
201606 -0.940 101.019 -1.230
201609 -0.830 101.138 -1.085
201612 -0.980 102.022 -1.270
201703 -1.270 102.022 -1.646
201706 -1.280 102.752 -1.647
201709 -1.060 103.279 -1.357
201712 -1.340 103.793 -1.707
201803 -1.230 103.962 -1.564
201806 -1.550 104.875 -1.954
201809 -1.610 105.679 -2.014
201812 -2.090 105.912 -2.609
201903 -1.810 105.886 -2.260
201906 -2.060 106.742 -2.551
201909 -2.360 107.214 -2.910
201912 -2.770 107.766 -3.398
202003 -2.330 106.563 -2.891
202006 -2.480 107.498 -3.050
202009 -2.770 107.635 -3.402
202012 -2.370 108.296 -2.893
202103 -2.340 108.360 -2.855
202106 -2.980 108.928 -3.617
202109 -3.340 110.338 -4.002
202112 -3.680 112.486 -4.325
202203 -3.110 114.825 -3.581
202206 -3.820 118.384 -4.266
202209 -3.450 122.296 -3.730
202212 -3.210 126.365 -3.358
202303 -3.920 127.042 -4.079
202306 -4.790 129.407 -4.894
202309 -4.780 130.224 -4.853
202312 -2.340 131.912 -2.345
202403 -4.150 132.205 -4.150

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Hansa Biopharma AB  (OSTO:HNSA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Hansa Biopharma AB Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansa Biopharma AB (OSTO:HNSA) Business Description

Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB (OSTO:HNSA) Headlines

No Headlines